Advertisement
AXON vs VCYT
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- AXON grew revenue 28% and software revenue 43% in its latest quarter, but cut its annual outlook after roughly $130 million in federal counter-drone deployments slipped into 2027.
- VCYT beat quarterly earnings estimates, yet its core Decipher Prostate franchise decelerated and management moderated its 2027 revenue growth outlook.
- Both stocks have pulled back sharply in recent weeks, making relative trend stability and recurring revenue quality the key differentiators in this stock comparison.
- Tickeron AI Verdict: AXON is the favored ticker, supported by a stronger recurring software revenue engine, a large contracted backlog, and more consistent long-term growth drivers despite near-term timing headwinds.
- For deeper context, explore AXON Major News and AXON Today's Price Move, as well as VCYT Major News and VCYT Today's Price Move.
- To see which stocks AI-powered systems are favoring right now, visit Trending AI Robots.
Introduction
Axon Enterprise (AXON) and Veracyte (VCYT) operate in unrelated industries — public safety technology versus genomic diagnostics — yet both are high-growth names that reward investors for understanding recurring revenue quality and execution consistency. This stock comparison is relevant for growth-oriented investors and traders weighing a hardware-to-software recurring model against a diagnostics platform built on test volumes. Both companies reported mixed results in recent weeks, and both shares have experienced notable volatility. Comparing their relative performance, market positioning, and trend quality helps clarify which stock currently presents the more consistent setup.
AXON Overview and Recent Performance
Axon Enterprise develops conducted energy weapons (TASERs), body cameras, and a growing suite of cloud-based software for law enforcement and public safety. The company has built a recurring software business on top of its hardware installed base, including digital evidence management, AI-assisted reporting, and real-time operations tools.
In its most recent quarterly report, AXON grew total revenue 28% to a record level, with software and services revenue up 43% and annual recurring revenue (ARR) rising 40%. Net revenue retention stood near 126%, and future contracted bookings climbed to roughly $15.8 billion. However, the quarter also brought a guidance reduction: three federal counter-drone (Dedrone) deployments worth about $130 million were delayed, lowering the full-year growth outlook to roughly 30% from a prior 32%–34% range. Management attributed the miss to procurement timing rather than lost demand. The shares sold off sharply in response, extending a challenging 2026 in which the stock has traded well below prior highs. Separately, Axon announced a $1.2 billion investment raising its stake in drone maker Skydio, positioning drones as a core platform.
VCYT Overview and Recent Performance
Veracyte is a genomic diagnostics company whose tests include Afirma (thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer), and Decipher Bladder (bladder cancer). Its business model centers on growing test volumes and expanding clinical guideline support across its franchises.
In its latest quarter, VCYT posted adjusted earnings per share (EPS) and revenue above consensus, with revenue reaching roughly $152 million. Afirma thyroid testing remained strong, with double-digit volume and revenue growth, and the company raised its full-year Afirma outlook. At the same time, Decipher Prostate volumes grew about 12% — below management's expectations — prompting a modest narrowing of the 2026 revenue guidance range and a more cautious 2027 outlook of roughly 10% test-volume growth but mid-single-digit revenue growth. The company continues to invest in newer offerings such as Prosigna and its TrueMRD platform. Recent weeks have seen a meaningful decline in the share price and at least one notable analyst downgrade, reflecting reduced visibility into near-term growth.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots from a marketplace of hundreds of automated systems that collectively trade thousands of different tickers. Because market conditions change, only the bots best suited to the current environment earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance record, and set of tickers it trades, giving users a range of statistical profiles to review rather than a single one-size-fits-all approach. For investors comparing names like AXON and VCYT, this resource offers a data-driven way to observe how automated strategies are positioning across the market. Explore the Trending AI Robots page to review the currently featured bots.
Head-to-Head Comparison
The two companies diverge sharply on business model and growth architecture. AXON operates a hardware-to-software flywheel: devices such as TASERs and body cameras generate an installed base that fuels high-margin, recurring software subscriptions. Its growth drivers include premium software adoption, AI features, and counter-drone expansion, though hardware margins face pressure from memory costs and federal contract timing. VCYT relies on test utilization and reimbursement, with growth tied to clinical evidence and guideline inclusion across its cancer-testing franchises.
On recent momentum, both names have weakened, but the character of the weakness differs. Axon's setback stems from a timing-related guidance cut even as its highest-margin, recurring segment accelerates. Veracyte's moderation reflects a genuine deceleration in its largest franchise and a more restrained forward outlook. Risk profiles also differ: Axon carries net debt after funding its Skydio investment and faces execution risk in drones, while Veracyte holds a net cash position but contends with reimbursement, competitive, and geopolitical exposure tied to its Israel operations. In terms of market positioning, Axon is a far larger, more diversified recurring-revenue business, whereas Veracyte offers a smaller, specialized diagnostics profile.
Tickeron AI Verdict
Based on observable factors such as trend consistency, recurring revenue quality, and relative positioning, Tickeron's AI would currently lean toward AXON. Despite its recent guidance cut, Axon retains accelerating software and services growth, roughly 40% ARR expansion, high net revenue retention, and a large contracted backlog — attributes that tend to support longer-term trend stability. Veracyte's core franchise deceleration and moderated 2027 outlook introduce greater uncertainty into its near-term growth trajectory. This verdict is probabilistic rather than definitive: Axon's path depends on resolving federal deployment timing and defending hardware margins, while Veracyte retains catalysts in new product launches that could re-accelerate growth. Neither outcome is guaranteed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and VCYT is a Hold.
AXON's Indicator enters downward trend
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 115 similar instances where the Aroon Indicator formed such a pattern. In 95 of the 115 cases the stock moved lower. This puts the odds of a downward move at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 49 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
VCYT sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for VCYT moved below the 200-day moving average on November 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VCYT as a result. In 84 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for VCYT turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 38 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
VCYT moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VCYT crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 205 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
VCYT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.399) is normal, around the industry mean (67.298). P/E Ratio (16.778) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. VCYT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
AXON | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 82 | 100 | |
SMR RATING 1..100 | 81 | 75 | |
PRICE GROWTH RATING 1..100 | 66 | 88 | |
P/E GROWTH RATING 1..100 | 79 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VCYT's Valuation (70) in the Biotechnology industry is in the same range as AXON (90). This means that VCYT’s stock grew similarly to AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as VCYT (100). This means that AXON’s stock grew similarly to VCYT’s over the last 12 months.
VCYT's SMR Rating (75) in the Biotechnology industry is in the same range as AXON (81). This means that VCYT’s stock grew similarly to AXON’s over the last 12 months.
AXON's Price Growth Rating (66) in the Biotechnology industry is in the same range as VCYT (88). This means that AXON’s stock grew similarly to VCYT’s over the last 12 months.
AXON's P/E Growth Rating (79) in the Biotechnology industry is in the same range as VCYT (97). This means that AXON’s stock grew similarly to VCYT’s over the last 12 months.
| AXON | VCYT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 78% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 71% | 2 days ago 75% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 86% |
| Advances ODDS (%) | 19 days ago 74% | 6 days ago 74% |
| Declines ODDS (%) | 5 days ago 70% | 2 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 75% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 83% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 5 bearish.
- VCYT’s TA Score: 4 bullish, 6 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +0.78% price change this week, while VCYT (@Medical Specialties) price change was +0.70% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -0.56%. For the same industry, the average monthly price growth was -2.75%, and the average quarterly price growth was -17.05%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.79%. For the same industry, the average monthly price growth was -7.29%, and the average quarterly price growth was +34.42%.
Reported Earning Dates
AXON is expected to report earnings on Mar 02, 2027.
VCYT is expected to report earnings on Mar 01, 2027.
Industries' Descriptions
@Aerospace & Defense (-0.56% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Medical Specialties (-1.79% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement